Systemic Scleroderma Treatment Market - Industry Growth & Trend Analysis (2024-2032)

Systemic Scleroderma Treatment Market Synopsis:

Systemic Scleroderma Treatment Market Size Was Valued at USD 1.65 Billion in 2023, and is Projected to Reach USD 2.60 Billion by 2032, Growing at a CAGR of 4.9% From 2024-2032.

Systemic scleroderma or systemic sclerosis is carcinogenic autoimmune disorders involving changes in the skin and blood vessels, as well as immune systems derangement. Systemic scleroderma treatment relating to the market involves treatment initiatives towards the systematized management of the disease and its manifestation.

The market for scleroderma treatment across the world has been growing rapidly over the past few years due to enhanced awareness, better diagnosing facilities, and hay-making in the field of treatment. On the basis of 2019 global market size, which was accounted for USD 1,380.91 million, it is predicted that the market will grow up to USD 1,887.95 million by the end of the forecast period, at a CAGR of 4.0%. This growth is however common mainly by the of off label therapy including branded, generics OTC and small molecule therapies.

The market is distributed where there are many players, each providing different therapeutic solutions. Major pharmaceutical firms have continued to seek ways of bringing in new therapies that meet the changed global trends of systemic scleroderma. Moreover, there are suitable reimbursement models, and enhanced governmental support for such research have also led the market growth. They may however be limited by factors such as lack of curative medicine and high costs in developed procedures among others.

Systemic Scleroderma Treatment Market Trend Analysis

Emergence of Targeted Therapies Revolutionizing Treatment

• One new atypical in the global treatment for systemic scleroderma is the relatively recent introduction of targeted therapies which is aimed at abolishing molecular mechanisms implicated in the pathogenesis of the disease. The above therapies are therefore designed to mold the immune response system and minimize fibrosis better than the past protocols. For example, immunosuppressants and endothelin’s receptor antagonists have successfully been under trial and have given some light at the end of the tunnel for the patients.
• Such treatments have emerged as a form of what is known as targeted therapies, or a new trend in medicine called personalized medicine whereby treatments are administered depending on the peculiarities of the diseases in question, not the patients.

Expanding Research and Development Activities Present Lucrative Opportunities

• The rise in spending on research and development activities makes them a large opportunity within the systemic scleroderma treatment market. Chemical houses are putting a lot of money in the search of new bioactive agents to treat or even perhaps control systemic scleroderma.
• Partnerships between universities, on one side, and industry players, on the other side, are helping advance the work and ensure that there is a rich pipeline of options waiting to be developed. Nearly, the recent improvements in the knowledge of the pathophysiology of the disease have enabled the emergence of great solutions. This extended frontier of R&D does not only come with the potential to improve patient’s quality of life, but it holds the potential for increased market growth in the later years.

Systemic Scleroderma Treatment Market Segment Analysis:

Systemic Scleroderma Treatment Market Segmented on the basis of drug class, disease type and By Treatment Type.

By Drug Class, Phosphodiesterase 5 inhibitors (PHA) segment is expected to dominate the market during the forecast period

• The various drug classes available for the systemic scleroderma treatment are major driving forces for the global systemic scleroderma treatment market. Anti-inflammatories are commonly used to reduce inflammation and thus decrease the inflammation, which causes more damage to tissue. These drugs assist in the decrease of inflammation and fibrosis, a condition normally found in systemic scleroderma. PHA is also important in managing the condition more especially in patients with pulmonary arterial hypertension which is prevalent among patients with scleroderma. These inhibitors act by dilating blood vessels and thereby reducing the workload on the heart and on the lungs.
• Furthermore, ERAs are employed to counteract the effects of endothelin a protein that narrows blood vessels and causes fibrosis. These agents are especially helpful in enhancing blood perfusion and on the lessening of vascular involvement of scleroderma patients. The fourth group of drugs which found relevance in treatment strategies of pulmonary hypertension involves prostacyclin analogues that work by widening blood cells and preventing coagulation. factors These are Calcium Channel Blockers which assist in the reduction of symptoms like Raynaud’s phenomenon in which blood vessels clamp up in reaction to cold or stress. Last but not least, Others are the other supportive therapies and drugs that are still under trial on the effectiveness for systemic sclerosis known to be unmet needs.

By Treatment Type, Pharmacological Therapy segment expected to held the largest share

• Pharmacological Therapy is the major treatment given to patients with systemic scleroderma because the condition’s chief focus is symptom control, plus halting or making efforts to reverse some of the effects of the condition including pulmonary hypertension, fibrosis, and vascular events. Thus the immunosuppressants which are endothelin receptor antagonists, phosphodiesterase 5 inhibitors and prostacyclin analogue are useful as these address the disease pathogenesis. These treatments are mostly administered by physicians to reduce inflammation, protect affected organs and increase patients’ physical comfort. Sometimes for similar indications biologics or other targeted therapies are being developed as more optimal treatment strategies depending on certain tumour characteristics of the patient.
• Apart from drugs used in the treatment of systemic scleroderma, Non-Pharmacological Therapy has been found to have a central role in treating Systemic Scleroderma. These treatment entails the use of nonsurgical approaches that aim at supporting drug treatments, in addition to modification of the patient’s behaviours and lifestyle changes. Others are conservative management like using Physical therapy to reduce joint stiffness and Risk of contractures as well as Occupational therapy to help in daily functioning. Others are the dietary modification, stress reduction, and pulmonary exercise for those with associated lung involvement. They are usually prescribed for individual patient, especially to enhance their qualities of life by reducing the severity of symptoms.

Systemic Scleroderma Treatment Market Regional Insights:

North America is Expected to Dominate the Market Over the Forecast period

• North America is expected to dominate the systemic scleroderma treatment market over the forecast period, driven by the region's advanced healthcare infrastructure, strong presence of key pharmaceutical companies, and increasing research and development activities. The rising prevalence of autoimmune diseases, along with growing awareness about systemic scleroderma and available treatment options, further supports market growth. Additionally, government initiatives to fund rare disease research and the availability of innovative biologics and immunosuppressants contribute to the region's leadership. The United States, in particular, plays a significant role due to its robust clinical trial landscape and high healthcare expenditure.

Active Key Players in the Systemic Scleroderma Treatment Market:

• Actelion Pharmaceuticals Ltd (Switzerland)
• Allergan (Ireland)
• Amgen Inc. (United States)
• Argentis Pharmaceuticals, LLC (United States)
• Aspen Holdings (South Africa)
• AstraZeneca (United Kingdom)
• Bayer AG (Germany)
• Biogen (United States)
• Boehringer Ingelheim International GmbH (Germany)
• Bristol-Myers Squibb Company (United States)
• Celgene Corporation (United States)
• Corbus Pharmaceuticals (United States)
• Eli Lilly and Company (United States)
• F. Hoffmann-La Roche Ltd (Switzerland)
• GlaxoSmithKline plc (United Kingdom)
• Johnson & Johnson Services, Inc. (United States)
• Mylan N.V. (United States)
• Novartis AG (Switzerland)
• Ono Pharmaceutical Co. Ltd (Japan)
• Pfizer Inc. (United States)
• Sanofi (France)
• Teva Pharmaceutical Industries Ltd. (Israel)
• United Therapeutics Corporation (United States)
• Other Active Players

Chapter 1: Introduction
 1.1 Scope and Coverage

Chapter 2:Executive Summary

Chapter 3: Market Landscape
 3.1 Market Dynamics
  3.1.1 Drivers
  3.1.2 Restraints
  3.1.3 Opportunities
  3.1.4 Challenges
 3.2 Market Trend Analysis
 3.3 PESTLE Analysis
 3.4 Porter's Five Forces Analysis
 3.5 Industry Value Chain Analysis
 3.6 Ecosystem
 3.7 Regulatory Landscape
 3.8 Price Trend Analysis
 3.9 Patent Analysis
 3.10 Technology Evolution
 3.11 Investment Pockets
 3.12 Import-Export Analysis

Chapter 4: Systemic Scleroderma Treatment Market by Drug Class
 4.1 Systemic Scleroderma Treatment Market Snapshot and Growth Engine
 4.2 Systemic Scleroderma Treatment Market Overview
 4.3 Immune suppressors
  4.3.1 Introduction and Market Overview
  4.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  4.3.3 Key Market Trends, Growth Factors and Opportunities
  4.3.4 Immune suppressors: Geographic Segmentation Analysis
 4.4 Phosphodiesterase 5 inhibitors (PHA)
  4.4.1 Introduction and Market Overview
  4.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  4.4.3 Key Market Trends, Growth Factors and Opportunities
  4.4.4 Phosphodiesterase 5 inhibitors (PHA): Geographic Segmentation Analysis
 4.5 Endothelin Receptor Antagonists
  4.5.1 Introduction and Market Overview
  4.5.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  4.5.3 Key Market Trends, Growth Factors and Opportunities
  4.5.4 Endothelin Receptor Antagonists: Geographic Segmentation Analysis
 4.6 Prostacyclin Analogues
  4.6.1 Introduction and Market Overview
  4.6.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  4.6.3 Key Market Trends, Growth Factors and Opportunities
  4.6.4 Prostacyclin Analogues: Geographic Segmentation Analysis
 4.7 Calcium Channel Blockers
  4.7.1 Introduction and Market Overview
  4.7.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  4.7.3 Key Market Trends, Growth Factors and Opportunities
  4.7.4 Calcium Channel Blockers: Geographic Segmentation Analysis
 4.8 Others
  4.8.1 Introduction and Market Overview
  4.8.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  4.8.3 Key Market Trends, Growth Factors and Opportunities
  4.8.4 Others: Geographic Segmentation Analysis

Chapter 5: Systemic Scleroderma Treatment Market by Treatment Type
 5.1 Systemic Scleroderma Treatment Market Snapshot and Growth Engine
 5.2 Systemic Scleroderma Treatment Market Overview
 5.3 Pharmacological Therapy
  5.3.1 Introduction and Market Overview
  5.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  5.3.3 Key Market Trends, Growth Factors and Opportunities
  5.3.4 Pharmacological Therapy: Geographic Segmentation Analysis
 5.4 Non-Pharmacological Therapy
  5.4.1 Introduction and Market Overview
  5.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  5.4.3 Key Market Trends, Growth Factors and Opportunities
  5.4.4 Non-Pharmacological Therapy: Geographic Segmentation Analysis

Chapter 6: Systemic Scleroderma Treatment Market by Disease Type
 6.1 Systemic Scleroderma Treatment Market Snapshot and Growth Engine
 6.2 Systemic Scleroderma Treatment Market Overview
 6.3 Limited Systemic Scleroderma
  6.3.1 Introduction and Market Overview
  6.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  6.3.3 Key Market Trends, Growth Factors and Opportunities
  6.3.4 Limited Systemic Scleroderma: Geographic Segmentation Analysis
 6.4 Diffuse Systemic Scleroderma
  6.4.1 Introduction and Market Overview
  6.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  6.4.3 Key Market Trends, Growth Factors and Opportunities
  6.4.4 Diffuse Systemic Scleroderma: Geographic Segmentation Analysis

Chapter 7: Company Profiles and Competitive Analysis
 7.1 Competitive Landscape
  7.1.1 Competitive Benchmarking
  7.1.2 Systemic Scleroderma Treatment Market Share by Manufacturer (2023)
  7.1.3 Industry BCG Matrix
  7.1.4 Heat Map Analysis
  7.1.5 Mergers and Acquisitions  
 7.2 ACTELION PHARMACEUTICALS LTD (SWITZERLAND)
  7.2.1 Company Overview
  7.2.2 Key Executives
  7.2.3 Company Snapshot
  7.2.4 Role of the Company in the Market
  7.2.5 Sustainability and Social Responsibility
  7.2.6 Operating Business Segments
  7.2.7 Product Portfolio
  7.2.8 Business Performance
  7.2.9 Key Strategic Moves and Recent Developments
  7.2.10 SWOT Analysis
 7.3 ALLERGAN (IRELAND)
 7.4 AMGEN INC. (UNITED STATES)
 7.5 ARGENTIS PHARMACEUTICALS LLC (UNITED STATES)
 7.6 ASPEN HOLDINGS (SOUTH AFRICA)
 7.7 ASTRAZENECA (UNITED KINGDOM)
 7.8 BAYER AG (GERMANY)
 7.9 BIOGEN (UNITED STATES)
 7.10 BOEHRINGER INGELHEIM INTERNATIONAL GMBH (GERMANY)
 7.11 BRISTOL-MYERS SQUIBB COMPANY (UNITED STATES)
 7.12 CELGENE CORPORATION (UNITED STATES)
 7.13 CORBUS PHARMACEUTICALS (UNITED STATES)
 7.14 ELI LILLY AND COMPANY (UNITED STATES)
 7.15 F. HOFFMANN-LA ROCHE LTD (SWITZERLAND)
 7.16 GLAXOSMITHKLINE PLC (UNITED KINGDOM)
 7.17 JOHNSON & JOHNSON SERVICES INC. (UNITED STATES)
 7.18 MYLAN N.V. (UNITED STATES)
 7.19 NOVARTIS AG (SWITZERLAND)
 7.20 OTHER ACTIVE PLAYERS

Chapter 8: Global Systemic Scleroderma Treatment Market By Region
 8.1 Overview
 8.2. North America Systemic Scleroderma Treatment Market
  8.2.1 Key Market Trends, Growth Factors and Opportunities
  8.2.2 Top Key Companies
  8.2.3 Historic and Forecasted Market Size by Segments
  8.2.4 Historic and Forecasted Market Size By Drug Class
  8.2.4.1 Immune suppressors
  8.2.4.2 Phosphodiesterase 5 inhibitors (PHA)
  8.2.4.3 Endothelin Receptor Antagonists
  8.2.4.4 Prostacyclin Analogues
  8.2.4.5 Calcium Channel Blockers
  8.2.4.6 Others
  8.2.5 Historic and Forecasted Market Size By Treatment Type
  8.2.5.1 Pharmacological Therapy
  8.2.5.2 Non-Pharmacological Therapy
  8.2.6 Historic and Forecasted Market Size By Disease Type
  8.2.6.1 Limited Systemic Scleroderma
  8.2.6.2 Diffuse Systemic Scleroderma
  8.2.7 Historic and Forecast Market Size by Country
  8.2.7.1 US
  8.2.7.2 Canada
  8.2.7.3 Mexico
 8.3. Eastern Europe Systemic Scleroderma Treatment Market
  8.3.1 Key Market Trends, Growth Factors and Opportunities
  8.3.2 Top Key Companies
  8.3.3 Historic and Forecasted Market Size by Segments
  8.3.4 Historic and Forecasted Market Size By Drug Class
  8.3.4.1 Immune suppressors
  8.3.4.2 Phosphodiesterase 5 inhibitors (PHA)
  8.3.4.3 Endothelin Receptor Antagonists
  8.3.4.4 Prostacyclin Analogues
  8.3.4.5 Calcium Channel Blockers
  8.3.4.6 Others
  8.3.5 Historic and Forecasted Market Size By Treatment Type
  8.3.5.1 Pharmacological Therapy
  8.3.5.2 Non-Pharmacological Therapy
  8.3.6 Historic and Forecasted Market Size By Disease Type
  8.3.6.1 Limited Systemic Scleroderma
  8.3.6.2 Diffuse Systemic Scleroderma
  8.3.7 Historic and Forecast Market Size by Country
  8.3.7.1 Russia
  8.3.7.2 Bulgaria
  8.3.7.3 The Czech Republic
  8.3.7.4 Hungary
  8.3.7.5 Poland
  8.3.7.6 Romania
  8.3.7.7 Rest of Eastern Europe
 8.4. Western Europe Systemic Scleroderma Treatment Market
  8.4.1 Key Market Trends, Growth Factors and Opportunities
  8.4.2 Top Key Companies
  8.4.3 Historic and Forecasted Market Size by Segments
  8.4.4 Historic and Forecasted Market Size By Drug Class
  8.4.4.1 Immune suppressors
  8.4.4.2 Phosphodiesterase 5 inhibitors (PHA)
  8.4.4.3 Endothelin Receptor Antagonists
  8.4.4.4 Prostacyclin Analogues
  8.4.4.5 Calcium Channel Blockers
  8.4.4.6 Others
  8.4.5 Historic and Forecasted Market Size By Treatment Type
  8.4.5.1 Pharmacological Therapy
  8.4.5.2 Non-Pharmacological Therapy
  8.4.6 Historic and Forecasted Market Size By Disease Type
  8.4.6.1 Limited Systemic Scleroderma
  8.4.6.2 Diffuse Systemic Scleroderma
  8.4.7 Historic and Forecast Market Size by Country
  8.4.7.1 Germany
  8.4.7.2 UK
  8.4.7.3 France
  8.4.7.4 The Netherlands
  8.4.7.5 Italy
  8.4.7.6 Spain
  8.4.7.7 Rest of Western Europe
 8.5. Asia Pacific Systemic Scleroderma Treatment Market
  8.5.1 Key Market Trends, Growth Factors and Opportunities
  8.5.2 Top Key Companies
  8.5.3 Historic and Forecasted Market Size by Segments
  8.5.4 Historic and Forecasted Market Size By Drug Class
  8.5.4.1 Immune suppressors
  8.5.4.2 Phosphodiesterase 5 inhibitors (PHA)
  8.5.4.3 Endothelin Receptor Antagonists
  8.5.4.4 Prostacyclin Analogues
  8.5.4.5 Calcium Channel Blockers
  8.5.4.6 Others
  8.5.5 Historic and Forecasted Market Size By Treatment Type
  8.5.5.1 Pharmacological Therapy
  8.5.5.2 Non-Pharmacological Therapy
  8.5.6 Historic and Forecasted Market Size By Disease Type
  8.5.6.1 Limited Systemic Scleroderma
  8.5.6.2 Diffuse Systemic Scleroderma
  8.5.7 Historic and Forecast Market Size by Country
  8.5.7.1 China
  8.5.7.2 India
  8.5.7.3 Japan
  8.5.7.4 South Korea
  8.5.7.5 Malaysia
  8.5.7.6 Thailand
  8.5.7.7 Vietnam
  8.5.7.8 The Philippines
  8.5.7.9 Australia
  8.5.7.10 New Zealand
  8.5.7.11 Rest of APAC
 8.6. Middle East & Africa Systemic Scleroderma Treatment Market
  8.6.1 Key Market Trends, Growth Factors and Opportunities
  8.6.2 Top Key Companies
  8.6.3 Historic and Forecasted Market Size by Segments
  8.6.4 Historic and Forecasted Market Size By Drug Class
  8.6.4.1 Immune suppressors
  8.6.4.2 Phosphodiesterase 5 inhibitors (PHA)
  8.6.4.3 Endothelin Receptor Antagonists
  8.6.4.4 Prostacyclin Analogues
  8.6.4.5 Calcium Channel Blockers
  8.6.4.6 Others
  8.6.5 Historic and Forecasted Market Size By Treatment Type
  8.6.5.1 Pharmacological Therapy
  8.6.5.2 Non-Pharmacological Therapy
  8.6.6 Historic and Forecasted Market Size By Disease Type
  8.6.6.1 Limited Systemic Scleroderma
  8.6.6.2 Diffuse Systemic Scleroderma
  8.6.7 Historic and Forecast Market Size by Country
  8.6.7.1 Turkiye
  8.6.7.2 Bahrain
  8.6.7.3 Kuwait
  8.6.7.4 Saudi Arabia
  8.6.7.5 Qatar
  8.6.7.6 UAE
  8.6.7.7 Israel
  8.6.7.8 South Africa
 8.7. South America Systemic Scleroderma Treatment Market
  8.7.1 Key Market Trends, Growth Factors and Opportunities
  8.7.2 Top Key Companies
  8.7.3 Historic and Forecasted Market Size by Segments
  8.7.4 Historic and Forecasted Market Size By Drug Class
  8.7.4.1 Immune suppressors
  8.7.4.2 Phosphodiesterase 5 inhibitors (PHA)
  8.7.4.3 Endothelin Receptor Antagonists
  8.7.4.4 Prostacyclin Analogues
  8.7.4.5 Calcium Channel Blockers
  8.7.4.6 Others
  8.7.5 Historic and Forecasted Market Size By Treatment Type
  8.7.5.1 Pharmacological Therapy
  8.7.5.2 Non-Pharmacological Therapy
  8.7.6 Historic and Forecasted Market Size By Disease Type
  8.7.6.1 Limited Systemic Scleroderma
  8.7.6.2 Diffuse Systemic Scleroderma
  8.7.7 Historic and Forecast Market Size by Country
  8.7.7.1 Brazil
  8.7.7.2 Argentina
  8.7.7.3 Rest of SA

Chapter 9 Analyst Viewpoint and Conclusion
9.1 Recommendations and Concluding Analysis
9.2 Potential Market Strategies

Chapter 10 Research Methodology
10.1 Research Process
10.2 Primary Research
10.3 Secondary Research